AACR21: Zentalis keeps the heat on AstraZeneca with early WEE1 data showing a group of 'exceptional' responders
Long a target for drugmakers, the DNA damage repair pathway has picked up some new steam in recent years with Big Pharma placing its bets. One of the leading candidates there is a WEE1 enzyme inhibitor from AstraZeneca, and now a small biotech player is looking to play catch up.
Zentalis’ WEE1 inhibitor, ZN-c3, posted partial responses across a slate of tumor types with a tolerable safety profile as monotherapy for solid tumor patients who are either treatment-resistant or have no established standard of care, according to interim Phase I data presented as a late breaker Saturday at the virtual AACR annual meeting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.